Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5+ mTNBC

Breast

This is a phase Ib / II Study of Leronlimab (PRO 140) combined with Carboplatin in Patients with CCR5+ Metastatic Triple Negative Breast Cancer (mTNBC). Study population will consist of patients with CCR5-positive, locally advanced or metastatic triple-negative breast cancer (mTNBC) who are naïve to chemotherapy in metastatic setting but have been exposed to anthracyclines and taxane in neoadjuvant and adjuvant settings (first-line).
Breast
I/II
Abramson, Vandana
NCT03838367
VICCBREP1983

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: